News

Novavax, Inc. announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its…
Read More...

Vaccitech Limited and the University of Oxford announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in…
Read More...

ProBioGen AG announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell Line Development, Process…
Read More...

AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of…
Read More...

Hoth Therapeutics, Inc. announced that it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be named HaloVax, to commence preclinical…
Read More...

In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. and SmartPharm Therapeutics Inc. (SmartPharm) announced a research and development…
Read More...

Flexipharm Austrading, the UK specialty pharmaceutical company focused on supplying the NHS with Better, Critical Care Medicines, announced an important improvement to the 'Summary of…
Read More...

Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING)…
Read More...

Takeda Pharmaceutical Company Limited has announced that the gut-selective biologic Entyvio (vedolizumab) was approved by China’s National Medical Products Administration (NMPA). The…
Read More...

Genentech, a member of the Roche Group announced that the Phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi).…
Read More...

Genentech, a member of the Roche Group announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial…
Read More...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
Read More...

As part of the U.S. Food and Drug Administration's ongoing efforts to address the coronavirus pandemic (COVID-19), the agency issued a new guidance to sponsors and healthcare providers…
Read More...

Tarveda Therapeutics, Inc. and SciClone Pharmaceuticals International Ltd. announced that they have entered into a licensing agreement for PEN-866, the initial clinical program from…
Read More...

Junshi Biosciences announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to jointly develop…
Read More...

Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University,…
Read More...

Dragonfly Therapeutics, Inc. announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and commercialize a…
Read More...

Novartis Pharma K.K. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy…
Read More...

Emergent BioSolutions Inc. announced that it has entered into an agreement with Vaxart, Inc. a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its…
Read More...

Roche announced we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with…
Read More...